Posted on 4/10/18
Zelis Healthcare and WLT Software Announce Partnership for Integrated ePayment Solutions
BEDMINSTER, N.J. & CLEARWATER, Fla.--(BUSINESS WIRE)--Zelis® Healthcare today announced a newly formed business alliance with WLT Software® to include integration with MediClaims, its comprehensive benefit and . . .
Posted on 4/8/18
Mylan Strengthens Its Capital Structure by Extending Its Debt Maturities with a Successful $1.5 Billion Bond Offering
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the pricing of a private offering of $1.5 billionaggregate principal amount of senior notes on March 28, . . .
Posted on 4/6/18
GNC Announces Plans to Expand into Australia
General Nutrition Corporation (NYSE: GNC) today announced plans to establish and develop a presence in the Australian market.Under a master franchise agreement, GNC will partner with . . .
Posted on 4/5/18
New Jersey Jury Finds J&J's Iconic Baby Powder Tainted By Asbestos
Johnson & Johnson (NYSE:JNJ) and talc mining company Imerys (OTC:IMYSF) are ordered by a New Jersey state court to pay at least $37Mto a plaintiff who . . .
Posted on 4/5/18
Teva, Valeant Exposed By California's Drug Transparency Law
California Governor Jerry BrownCalifornia and Vermont have been in the forefront of the drug price debate. They have both attempted to shine a light on drug . . .
Posted on 4/5/18
Pfizer Has Big Plans in Treating Lung Cancer
Pfizer Inc. (NYSE:PFE) already markets the $600-million-per-year lung cancer drug Xalkori, and next year, it could have two more lung cancer drugs on the market. Recently, . . .
Posted on 4/5/18
Alkermes' Bad News Could Be Good News for Johnson & Johnson
Alkermes'(NASDAQ:ALKS) hopes for a speedy review of its depression drug ALKS-5461 were dashed earlier this week when the Food and Drug Administration (FDA) issued it a . . .
Posted on 4/5/18
Windtree Therapeutics Announces Closing of $2.6 Million Private Placement
Windtree Therapeutics, Inc. (OTCQB: WINT),a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has closed a $2.6 million . . .
Posted on 4/4/18
MTBC Announces $10.5 Million Public Offering of Non-Convertible Preferred Stock
SOMERSET, N.J., April 04, 2018 (GLOBE NEWSWIRE) -- MTBC (NASDAQ: MTBC) (NASDAQ: MTBCP), a leading provider of proprietary, cloud-based healthcare IT solutions and services, today announced . . .
Posted on 4/4/18
SteroTherapeutics Receives FDA Orphan-Drug Designation
PHILADELPHIA, April 04, 2018 (GLOBE NEWSWIRE) -- SteroTherapeutics, a privately held biopharmaceutical company developing therapies focused on metabolic diseases including non-alcoholic steatohepatitis (NASH), announced today that . . .
Posted on 4/4/18
How Worried Should Alnylam and Ionis Really Be About Pfizer's New Data?
Last week, Pfizer (NYSE:PFE) released positive results from its ATTR-ACT phase 3 trial testing tafamidis for patients with a rare disease called transthyretin (TTR) amyloidosis cardiomyopathy, . . .
Posted on 4/3/18
Medical Guardian Named a Top Workplace in Philadelphia
PHILADELPHIA--(BUSINESS WIRE)--Medical Guardian, a leading provider of innovative medical alert systems, is honored to once again be recognized as a Top Workplace in the Greater Philadelphia . . .
Posted on 4/3/18
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WAYNE, Pa., April 03, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies . . .
Posted on 4/3/18
Why Pfizer's Big Win Is Bad News for Alnylam and Ionis
Pfizer Inc. (NYSE:PFE) recently scored a clinical trial win with a rare-disease drug the Food and Drug Administration rejected about six years ago. The big U.S. . . .
Posted on 4/3/18
Idera Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with BioCryst Pharmaceuticals
EXTON, Pa., April 02, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel . . .
Posted on 4/2/18
UBM Americas’ Pharmaceutical Executive Opens Nominations for 2018 Emerging Pharma Leaders
ISELIN, N.J., April 02, 2018 (GLOBE NEWSWIRE) -- UBM Life Sciences Group’s Pharmaceutical Executive today opened nominations for Emerging Pharma Leaders, an awards program that for . . .
Posted on 4/2/18
Idera Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with BioCryst Pharmaceuticals
EXTON, Pa., April 02, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic . . .
Posted on 4/2/18
STRATA Skin Sciences Reports Fourth Quarter and Fiscal Year 2017 Financial Results
HORSHAM, Pa., April 02, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ:SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, . . .
Posted on 4/2/18
Better Buy: Celgene Corporation vs. Gilead Sciences
Biotech stocks have been outstanding growth vehicles for investors over the better part of the last decade. Top dogs like Celgene Corp. (NASDAQ:CELG) and Gilead Sciences(NASDAQ:GILD), . . .
Posted on 4/2/18
Is Celgene a Beaten-Up Biotech Stock to Buy?
Biotechs are exposed to a litany of risks including patent expiration, clinical-trial failures, and advances by competitors. That can make it one of the trickiest industries . . .
Posted on 4/2/18
Is Pfizer Inc. a Buy?
Suppose it's April 2015. Someone asks you, "Is Pfizer (NYSE:PFE) a good stock to buy?" At the time, the big pharma company's sales and earnings were . . .
Posted on 4/2/18
Better Buy: AbbVie Inc. vs. Johnson & Johnson
AbbVie (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) battle each other in the marketplace every day. But they also are partners. That's not an unusual scenario in . . .
Posted on 3/29/18
Citius Announces $2.0 Million Registered Direct Offering Priced At-the-Market
Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into . . .
Posted on 3/29/18
Children's Hospital of Philadelphia Named Leader in LGBTQ Healthcare Equality
For the fourth year in a row, Children's Hospital of Philadelphia (CHOP) has been recognized as an LGBTQ Healthcare Equality Leader by the Human Rights Campaign . . .
Posted on 3/29/18
Forget Merck: Novavax, Inc. Is a Better Vaccine Stock
Could Novavax, Inc. (NASDAQ:NVAX) be a better vaccine stock than Merck (NYSE:MRK)? I think so.That might sound crazy. After all, Novavax is tiny and unproven. It's . . .

